HCP, Inc. is a self-administered real estate investment trust. The company has market cap of $14.62 billion. The Firm invests in real estate serving the healthcare industry in the United States. It has a 40.15 P/E ratio. The Company’s divisions include senior housing triple-net , senior housing operating portfolio (SHOP), life science and medical office.
The stock of Accelerate Diagnostics Inc (NASDAQ:AXDX) is a huge mover today! About 84,935 shares traded. Accelerate Diagnostics Inc (NASDAQ:AXDX) has risen 2.17% since August 22, 2016 and is uptrending. It has underperformed by 5.89% the S&P500.The move comes after 7 months negative chart setup for the $1.24B company. It was reported on Mar, 29 by Barchart.com. We have $21.11 PT which if reached, will make NASDAQ:AXDX worth $111.60M less.
Analysts await HCP, Inc. (NYSE:HCP) to report earnings on May, 8. They expect $0.49 earnings per share, down 28.99% or $0.20 from last year’s $0.69 per share. HCP’s profit will be $231.09 million for 15.82 P/E if the $0.49 EPS becomes a reality. After $0.59 actual earnings per share reported by HCP, Inc. for the previous quarter, Wall Street now forecasts -16.95% negative EPS growth.
Heitman Real Estate Securities Llc holds 3.93% of its portfolio in HCP, Inc. for 2.13 million shares. Security Capital Research & Management Inc owns 2.96 million shares or 2.86% of their US portfolio. Moreover, Daiwa Securities Group Inc. has 2.61% invested in the company for 13.69 million shares. The California-based Sfe Investment Counsel has invested 2.46% in the stock. Independent Order Of Foresters, a Ontario – Canada-based fund reported 94,715 shares.
Since January 1, 0001, it had 0 insider buys, and 1 sale for $299,409 activity.
It is down 13.65% since August 22, 2016 and is downtrending. It has underperformed by 21.71% the S&P500.
Ratings analysis reveals 13% of HCP’s analysts are positive. Out of 16 Wall Street analysts rating HCP, 2 give it “Buy”, 1 “Sell” rating, while 13 recommend “Hold”. The lowest target is $30 while the high is $41. The stock’s average target of $33.62 is 8.45% above today’s ($31) share price. HCP was included in 33 notes of analysts from September 8, 2015. RBC Capital Markets maintained the stock with “Underperform” rating in Friday, November 6 report. The stock of HCP, Inc. (NYSE:HCP) earned “Hold” rating by Evercore on Tuesday, September 8. As per Wednesday, June 22, the company rating was downgraded by Morgan Stanley. The rating was upgraded by Morgan Stanley on Monday, March 20 to “Equal-Weight”. As per Wednesday, March 16, the company rating was downgraded by UBS. Mizuho upgraded the shares of HCP in report on Monday, November 21 to “Buy” rating. Evercore upgraded the shares of HCP in report on Monday, March 27 to “In-Line” rating. On Thursday, March 10 the stock rating was maintained by Barclays Capital with “Underweight”. The company was maintained on Wednesday, November 2 by Mizuho. JP Morgan maintained HCP, Inc. (NYSE:HCP) on Tuesday, March 15 with “Neutral” rating.
Accelerate Diagnostics, Inc. is an in vitro diagnostics firm engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The company has market cap of $1.24 billion. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify , infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It currently has negative earnings. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results.
Among 4 analysts covering Accelerate Diagnostics (NASDAQ:AXDX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Accelerate Diagnostics had 5 analyst reports since August 25, 2015 according to SRatingsIntel. The rating was initiated by William Blair with “Outperform” on Friday, January 8. JP Morgan initiated Accelerate Diagnostics Inc (NASDAQ:AXDX) rating on Thursday, March 24. JP Morgan has “Overweight” rating and $17 target. The stock of Accelerate Diagnostics Inc (NASDAQ:AXDX) earned “Neutral” rating by BTIG Research on Tuesday, August 25. On Tuesday, August 9 the stock rating was maintained by JP Morgan with “Overweight”. On Wednesday, December 16 the stock rating was initiated by Piper Jaffray with “Overweight”.
Since January 9, 2017, it had 3 insider buys, and 1 sale for $ activity. On Monday, January 9 the insider Mehren Lawrence sold $7.60 million. Another trade for 52,700 shares valued at $1.00 million was bought by PATIENCE JOHN. Strobeck Matthew bought $152,000 worth of stock. On Monday, January 9 SCHULER JACK W bought $6.45 million worth of Accelerate Diagnostics Inc (NASDAQ:AXDX) or 339,368 shares.
